MX356525B - Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. - Google Patents
Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.Info
- Publication number
- MX356525B MX356525B MX2013009604A MX2013009604A MX356525B MX 356525 B MX356525 B MX 356525B MX 2013009604 A MX2013009604 A MX 2013009604A MX 2013009604 A MX2013009604 A MX 2013009604A MX 356525 B MX356525 B MX 356525B
- Authority
- MX
- Mexico
- Prior art keywords
- choroideremia
- gene therapy
- aav
- vectors
- prevention
- Prior art date
Links
- 208000033810 Choroidal dystrophy Diseases 0.000 title abstract 2
- 208000003571 choroideremia Diseases 0.000 title abstract 2
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1103062.4A GB201103062D0 (en) | 2011-02-22 | 2011-02-22 | Method |
| PCT/GB2012/050376 WO2012114090A1 (en) | 2011-02-22 | 2012-02-21 | Aav -vectors for use in gene therapy of choroideremia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013009604A MX2013009604A (es) | 2013-09-16 |
| MX356525B true MX356525B (es) | 2018-06-01 |
Family
ID=43881504
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013009604A MX356525B (es) | 2011-02-22 | 2012-02-21 | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. |
| MX2018006733A MX388146B (es) | 2011-02-22 | 2012-02-21 | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006733A MX388146B (es) | 2011-02-22 | 2012-02-21 | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9834788B2 (enExample) |
| EP (2) | EP2678435B2 (enExample) |
| JP (4) | JP2014512171A (enExample) |
| KR (3) | KR102299430B1 (enExample) |
| CN (2) | CN107881198A (enExample) |
| AU (2) | AU2012220404B2 (enExample) |
| BR (1) | BR112013021318B1 (enExample) |
| CA (1) | CA2827975C (enExample) |
| DK (1) | DK2678435T3 (enExample) |
| ES (1) | ES2676550T5 (enExample) |
| GB (1) | GB201103062D0 (enExample) |
| HK (2) | HK1258917A1 (enExample) |
| IL (1) | IL228031B (enExample) |
| MX (2) | MX356525B (enExample) |
| PL (1) | PL2678435T3 (enExample) |
| PT (1) | PT2678435T (enExample) |
| SG (1) | SG192911A1 (enExample) |
| WO (1) | WO2012114090A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201103062D0 (en) † | 2011-02-22 | 2011-04-06 | Isis Innovation | Method |
| CN105980569A (zh) | 2013-08-05 | 2016-09-28 | 莱顿大学医学中心附属莱顿教学医院 | 重组aav-crumbs同源物组合物及治疗lca-8和进行性rp的方法 |
| KR102281881B1 (ko) * | 2013-12-06 | 2021-07-27 | 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) | 대상체의 망막 색소 상피에서 목적 폴리뉴클레오티드를 발현시키기 위한 방법 및 약학적 조성물 |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| EP3215191B1 (en) | 2014-11-05 | 2024-08-14 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| US20180043034A1 (en) * | 2015-03-06 | 2018-02-15 | Massachusetts Eye And Ear Infirmary | Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene |
| CN109069668B (zh) | 2015-12-14 | 2023-04-18 | 宾夕法尼亚州大学信托人 | 用于眼病的基因疗法 |
| GB201604146D0 (en) | 2016-03-10 | 2016-04-27 | Nightstarx Ltd | Prenylation assay |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| IL297576B2 (en) | 2016-05-18 | 2024-02-01 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| EP3831281B1 (en) | 2016-08-30 | 2026-02-25 | The Regents of The University of California | Devices and systems for biomedical targeting and delivery |
| US10633689B2 (en) | 2016-11-07 | 2020-04-28 | Spark Therapeutics, Inc. | Rab Escort Protein potency assay |
| US11938197B2 (en) * | 2017-01-10 | 2024-03-26 | The Sydney Children's Hospitals Network (Randwick And Westmead (Incorporating The Royal Alexandra Hospital For Children) | Polynucleotides and vectors for the expression of transgenes |
| US10550405B2 (en) | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| US11827898B2 (en) | 2017-06-14 | 2023-11-28 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| MX2020003042A (es) | 2017-09-29 | 2020-11-18 | Voyager Therapeutics Inc | Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa. |
| MX2020004005A (es) * | 2017-10-03 | 2020-10-05 | Prevail Therapeutics Inc | Terapias genicas para los trastornos lisosomales. |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| AU2018352986A1 (en) | 2017-10-17 | 2020-05-14 | Nightstarx Limited | Prenylation assay |
| KR20200119782A (ko) * | 2017-12-06 | 2020-10-20 | 오비드 테라퓨틱스 인크. | 발작 장애 치료 시 mir101 또는 mir128의 용도 |
| WO2019152841A1 (en) | 2018-02-01 | 2019-08-08 | Homology Medicines, Inc. | Adeno-associated virus compositions for pah gene transfer and methods of use thereof |
| AU2019215152A1 (en) | 2018-02-01 | 2020-08-20 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof |
| US11306329B2 (en) | 2018-02-19 | 2022-04-19 | City Of Hope | Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof |
| EP3775234A1 (en) * | 2018-04-05 | 2021-02-17 | NightstaRx Limited | Aav compositions, methods of making and methods of use |
| AU2018422759B2 (en) * | 2018-05-07 | 2026-01-22 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| CN112424359A (zh) | 2018-05-15 | 2021-02-26 | 沃雅戈治疗公司 | 用于治疗帕金森氏病的组合物和方法 |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| US20220193261A1 (en) * | 2019-04-30 | 2022-06-23 | The Trustees Of The University Of Pennsylvania | Compositions useful for treatment of pompe disease |
| TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| IL300526A (en) | 2020-08-17 | 2023-04-01 | Massachusetts Inst Technology | Approaches to SHANK3 gene therapy |
| WO2022109247A1 (en) | 2020-11-20 | 2022-05-27 | Biogen Ma Inc. | Viral vector potency assay |
| EP4482970A1 (en) | 2022-02-23 | 2025-01-01 | Massachusetts Institute of Technology | Methods for upregulating shank3 expression |
| JP2025528188A (ja) | 2022-08-11 | 2025-08-26 | インスティテュート オブ モレキュラー アンド クリニカル オフサルモロジー バーゼル （アイオービー） | ヒト錐体光受容体オプトジェネティクス構築物 |
| AU2023323327A1 (en) | 2022-08-11 | 2025-02-13 | Institute Of Molecular And Clinical Ophthalmology Basel (Iob) | Promoters for specific expression of genes in cone photoreceptors |
| CN121794288A (zh) | 2023-05-05 | 2026-04-03 | 麻省理工学院 | Shank3基因治疗方法 |
| WO2025090942A1 (en) * | 2023-10-26 | 2025-05-01 | University Of Notre Dame Du Lac | Gene therapy for treatment of neurometabolic disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0856585A1 (en) | 1997-01-29 | 1998-08-05 | Introgene B.V. | A conditional replication and expression system |
| EP1228234A2 (en) * | 2000-03-14 | 2002-08-07 | Neurologix, Inc. | Production of chimeric capsid vectors |
| CA2442670A1 (en) * | 2001-04-13 | 2002-10-24 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
| US20040208847A1 (en) * | 2003-03-28 | 2004-10-21 | Fabienne Rolling | Method and vectors for selectively transducing retinal pigment epithelium cells |
| WO2006090689A1 (ja) * | 2005-02-23 | 2006-08-31 | Dnavec Corporation | Siv-pedfベクターを用いた眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬 |
| AU2006242371A1 (en) * | 2005-04-29 | 2006-11-09 | The University Of North Carolina At Chapel Hill | Methods and compositions for regulated expression of nucleic acid at post-transcriptional level |
| US20090022731A1 (en) * | 2006-08-25 | 2009-01-22 | Wyeth | Arthritis-associated B cell gene expression |
| US20100278843A1 (en) * | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| EP2242840B1 (en) * | 2008-01-29 | 2019-07-24 | Applied Genetic Technologies Corporation | Recombinant adeno-associated virus production using bhk cells in suspension |
| CA2713755A1 (en) * | 2008-02-07 | 2009-08-13 | Ceregene, Inc. | Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein |
| SI3988660T1 (sl) * | 2009-05-02 | 2025-09-30 | Genzyme Corporation | Genska terapija za nevrodegenerativne motnje |
| US9169494B2 (en) | 2010-01-12 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| GB201103062D0 (en) † | 2011-02-22 | 2011-04-06 | Isis Innovation | Method |
-
2011
- 2011-02-22 GB GBGB1103062.4A patent/GB201103062D0/en not_active Ceased
-
2012
- 2012-02-21 CN CN201710784145.9A patent/CN107881198A/zh active Pending
- 2012-02-21 CA CA2827975A patent/CA2827975C/en active Active
- 2012-02-21 US US14/000,836 patent/US9834788B2/en active Active
- 2012-02-21 EP EP12706308.9A patent/EP2678435B2/en active Active
- 2012-02-21 KR KR1020207021515A patent/KR102299430B1/ko not_active Expired - Fee Related
- 2012-02-21 BR BR112013021318-3A patent/BR112013021318B1/pt not_active IP Right Cessation
- 2012-02-21 PL PL12706308T patent/PL2678435T3/pl unknown
- 2012-02-21 MX MX2013009604A patent/MX356525B/es active IP Right Grant
- 2012-02-21 KR KR1020137024782A patent/KR102139203B1/ko not_active Expired - Fee Related
- 2012-02-21 AU AU2012220404A patent/AU2012220404B2/en not_active Ceased
- 2012-02-21 PT PT127063089T patent/PT2678435T/pt unknown
- 2012-02-21 CN CN201280019547.5A patent/CN103562396A/zh active Pending
- 2012-02-21 ES ES12706308T patent/ES2676550T5/es active Active
- 2012-02-21 WO PCT/GB2012/050376 patent/WO2012114090A1/en not_active Ceased
- 2012-02-21 EP EP18172129.1A patent/EP3428283A1/en not_active Withdrawn
- 2012-02-21 DK DK12706308.9T patent/DK2678435T3/en active
- 2012-02-21 KR KR1020217028082A patent/KR20210112407A/ko not_active Ceased
- 2012-02-21 MX MX2018006733A patent/MX388146B/es unknown
- 2012-02-21 SG SG2013063797A patent/SG192911A1/en unknown
- 2012-02-21 JP JP2013554938A patent/JP2014512171A/ja active Pending
-
2013
- 2013-08-19 IL IL228031A patent/IL228031B/en active IP Right Grant
-
2014
- 2014-05-23 HK HK19101394.9A patent/HK1258917A1/en unknown
-
2017
- 2017-06-14 JP JP2017117286A patent/JP2017221192A/ja active Pending
- 2017-07-20 AU AU2017206254A patent/AU2017206254A1/en not_active Abandoned
- 2017-10-31 US US15/799,852 patent/US20180135078A1/en not_active Abandoned
-
2018
- 2018-07-13 HK HK18109118.8A patent/HK1249548A1/zh unknown
-
2019
- 2019-11-05 JP JP2019201092A patent/JP2020054345A/ja active Pending
-
2020
- 2020-01-24 US US16/751,699 patent/US20210032656A1/en not_active Abandoned
-
2022
- 2022-10-26 US US17/974,466 patent/US20230332176A1/en not_active Abandoned
- 2022-12-02 JP JP2022193831A patent/JP2023036618A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201103062D0 (en) | Method | |
| PH12019502292A1 (en) | Methods and compositions for treatment of a genetic condition | |
| IN2014DN00288A (enExample) | ||
| IN2014DN00286A (enExample) | ||
| IN2014MN00093A (enExample) | ||
| PH12015500525A1 (en) | Formulations of enzalutamide | |
| IN2014MN01378A (enExample) | ||
| NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| IN2014DN06792A (enExample) | ||
| SMT201800380T1 (it) | Terapia combinata per il trattamento di sclerosi multipla | |
| PL2804599T3 (pl) | Terapia skojarzona do leczenia nowotworu złośliwego | |
| SG10201703677VA (en) | Methods of treating s. aureus-associated diseases | |
| IN2014DN00254A (enExample) | ||
| IL275636A (en) | Medical combination for cancer treatment | |
| ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
| UA117567C2 (uk) | Композиція, яка стимулює лактацію, на основі фосфатидилсерину | |
| EP3449917A3 (en) | Tapentadol for preventing chronification of pain | |
| HUE040124T2 (hu) | Diaminooxidázt tartalmazó helyi alkalmazású kompozíciók, magas hisztamin-szinttel társult, a fájdalom növekedésével járó betegségek kezelésére vagy megelõzésére | |
| HK40043513B (en) | Interval therapy for the treatment of eye diseases | |
| IL233495A0 (en) | Combination for cancer treatment | |
| AU2012900286A0 (en) | "Methods of treatment or prophylaxis" | |
| AU2012902296A0 (en) | Compositions for Therapy and Methods of Treatment | |
| GB201219696D0 (en) | Agents for the prevention and/or treatment of central nervous system damamge |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |